Results 121 to 130 of about 26,042 (243)

Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy. [PDF]

Clin Case Rep, 2022
D'Addona M, Pezzullo L, Giudice V, Serio B, Baldi C, Zeppa P, Selleri C.   +6 more
europepmc   +1 more source

Method Development, Validation and Degradation Studies of Imatinib Mesylate by UPLC

, 2021
Punna Venkateshwarlu, Mehul Patel
openalex   +2 more sources

Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response. [PDF]

Ann Hematol, 2023
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I.   +11 more
europepmc   +1 more source

Conformational landscape and low lying excited states of imatinib [PDF]

, 2016
The conformational changes of imatinib (IMT) are crucial for understanding the ligand–receptor interaction and its mechanism of action [Agofonov et al. (2014) Nature Struct Mol Biol 21:848–853].
Cainap, Calin, Chis, Vasile, Luchian, Raluca, Ramalho, João P. Prates, Stan, Nicoleta-Florina, Vinteler, Emil   +5 more
core  

Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells. [PDF]

Iran J Basic Med Sci, 2023
Kamyabi R, Jahandideh A, Panahi N, Muhammadnejad S.   +3 more
europepmc   +1 more source

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate [PDF]

, 2003
Junya Kuroda
openalex   +1 more source

A Validated Liquid Chromatographic Method for the Estimation of Imatinib Mesylate in Dosage Forms: Application to Chemometrics based Robustness Testing and Greenness Assessment

, 2023
Sagar Suman Panda, Satyapriya Mohanty, Veera Shakar Pulusu, Sunil Kumar Sahu, B. Das   +4 more
openalex   +2 more sources

The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas. [PDF]

PLoS Pathog, 2023
Cleverley TL, Peddineni S, Guarner J, Cingolani F, Garcia PK, Koehler H, Mocarski ES, Kalman D.   +7 more
europepmc   +1 more source

What is the appropriate duration of adjuvant imatinib mesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture?

, 2019
Jun Lü, Yun Dai, Hua‐Long Zheng, Jian‐Wei Xie, Jia-Bin Wang, Jian‐Xian Lin, Qi‐Yue Chen, Long‐Long Cao, Mi Lin, Ru‐Hong Tu, Ze‐Ning Huang, Ju‐Li Lin, Ping Li, Chang‐Ming Huang, Chao‐Hui Zheng   +14 more
openalex   +1 more source

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response. [PDF]

Ann Hematol, 2023
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I.   +11 more
europepmc   +1 more source